Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 20, 2019updated 23 Dec 2019 8:33am

Boehringer and Lily report post-hoc analysis data of empagliflozin

Boehringer Ingelheim and Eli Lilly have reported positive findings from the post-hoc analysis of the EMPA-REG OUTCOME clinical trial of empagliflozin performed in adults with type 2 diabetes and established cardiovascular disease.

Boehringer Ingelheim and Eli Lilly have reported positive findings from the post-hoc analysis of the EMPA-REG OUTCOME clinical trial of empagliflozin performed in adults with type 2 diabetes and established cardiovascular disease.

The trial was conducted to evaluate if cardiovascular benefits are based on the number of cardiovascular risk factor goals reached.

According to the analysis results, the drug led to a decrease in the risk of cardiovascular death, hospitalisation for heart failure and 3P-MACE, irrespective of the number of risk factor goals achieved.

Boehringer Ingelheim CardioMetabolic Medicine corporate vice-president and head Waheed Jamal said: “Reducing cardiovascular risk in people with type 2 diabetes can be challenging, particularly in those with uncontrolled cardiovascular risk factors, such as blood sugar levels and blood pressure.

“It is therefore encouraging to see these findings from the EMPA-REG OUTCOME trial in which empagliflozin was shown to improve cardiovascular outcomes in people with type 2 diabetes and cardiovascular disease, irrespective of whether cardiovascular risk factors were controlled.”

Empagliflozin is an oral, selective sodium-glucose cotransporter 2 (SGLT2) inhibitor intended for the treatment of type 2 diabetes. It is believed that the sugar, salt and water metabolism changes induced by the drug may be responsible for cardiovascular death reductions.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The long-term, multi-centre, randomised, double-blind, placebo-controlled EMPA-REG OUTCOME trial involved more than 7,000 patients across 42 countries.

It investigated 10mg and 25mg once-daily empagliflozin in combination with standard of care, compared to placebo plus standard of care consisting of glucose-lowering agents and cardiovascular drugs.

The primary endpoint of the study was time to the first occurrence of cardiovascular death, non-fatal heart attack, or non-fatal stroke.

A 38%, 35% and 14% reduction was observed in the risk of cardiovascular death, hospitalisation for heart failure and 3P-MACE, respectively, in patients treated with the drug combination.

The post-hoc analysis showed that cardiovascular benefits were independent of the number of risk factor goals achieved.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU